Success in ED trials is measured as improvement in erectile function scores, increased frequency of adequate erections, or reduced phosphodiesterase-5-inhibitor dosage requirement. Approximately 45–65% of treated patients reported improvement in erectile rigidity, tumescence duration, or frequency of successful intercourse within 3–6 months of treatment. Approximately 20–35% achieved sufficient improvement to reduce or discontinue pharmacological agents. Response is better in younger men (<60 years), those with vasculogenic ED (not pure neurogenic ED), and those without severe diabetes or advanced atherosclerotic disease. Approximately 30–40% reported minimal or no functional change.
Erectile dysfunction trials remain relatively small and heterogeneous in outcome measurement. Five actively recruiting studies suggest ongoing clinical interest and demand. Published data report improvements in erectile function scores (International Index of Erectile Function or similar validated scales) following MSC or exosome infusion, with approximately 40–60% of treated patients showing measurable functional improvement within 3–6 months. Some trials documented improved response to phosphodiesterase-5 inhibitors in previously non-responsive patients. Duplex ultrasound studies showed improved cavernous artery flow in responsive cohorts. However, many studies lack sham-procedure controls; placebo effect is substantial in ED trials. Durability and long-term function beyond 12–24 months remain inadequately documented. Mechanism studies provide plausible biological rationale but lack definitive in-vivo confirmation.
Am I a candidate? → · Erectile Dysfunction: full overview → · Erectile Dysfunction cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment